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Abstract
Ouabain increases vascular resistance and may induce hypertension by
inhibiting the Na+ pump. The effects of 0.18 and 18 µg/kg, and 1.8 mg/
kg ouabain pretreatment on the phenylephrine (PHE; 0.1, 0.25 and 0.5
µg, in bolus)-evoked pressor responses were investigated using anesthe-
tized normotensive (control and uninephrectomized) and hypertensive
(1K1C and DOCA-salt treated) rats. Treatment with 18 µg/kg ouabain
increased systolic and diastolic blood pressure in all groups studied.
However, the magnitude of this increase was larger for the hypertensive
1K1C and DOCA-salt rats than for normotensive animals, while the
pressor effect of 0.18 µg/kg ouabain was greater only in DOCA-salt rats.
A very large dose (1.8 mg/kg) produced toxic effects on the normoten-
sive control but not on uninephrectomized or 1K1C rats. Rat tail vascular
beds were perfused to analyze the effects of 10 nM ouabain on the
pressor response to PHE. In all animals, 10 nM ouabain increased the
PHE pressor response, but this increase was larger in hypertensive
DOCA-salt rats than in normotensive and 1K1C rats. Results suggested
that a) increases in diastolic blood pressure induced by 18 µg/kg ouabain
were larger in hypertensive than normotensive rats; b) in DOCA-salt rats,
smaller ouabain doses had a stronger effect than in other groups; c)
hypertensive and uninephrectomized rats were less sensitive to toxic
doses of ouabain, and d) after treatment with 10 nM ouabain isolated tail
vascular beds from DOCA-salt rats were more sensitive to the pressor
effect of PHE than those from normotensive and 1K1C hypertensive rats.
These data suggest that very small doses of ouabain, which might
produce nanomolar plasma concentrations, enhance pressor reactivity in
DOCA-salt hypertensive rats, supporting the idea that endogenous
ouabain may contribute to the increase and maintenance of vascular tone
in hypertension.
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Introduction
Previous reports have shown that oua-
bain pretreatment of normotensive rats en-
hances arterial blood pressure and vasopres-
sor responses to vasoconstrictor agents in
vivo and in vitro (1,2). In vivo, the sensitiza-
tion induced by ouabain was also observed
in spontaneously hypertensive rats (SHR)
(1). However, the increment of pressor re-
sponses showed a difference between nor-
motensive rats and SHR. The SHR presented
enhanced pressor responses after adminis-
tration of very low doses of ouabain, which
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were not enough to induce the same effect in
normotensive rats (1).
In vitro, we also demonstrated that both
100 µM and 10 nM ouabain enhance the
vasoactive responses elicited by phenyleph-
rine in rat tail arteries (1,2). In these prepara-
tions the enhancement of the vasoconstrictor
responses to phenylephrine was greater in
SHR (1).
The sensitization produced by ouabain is
caused by the inhibition of the Na+ pump (3).
A reduction in Na+ pump activity leads to
Na+ accumulation in the myoplasm (4). The
Na+ increment affects the Na+/Ca2+ exchange
mechanism and consequently increases
the amount of activator Ca2+ necessary
for contraction of vascular smooth muscle
(4,5). Therefore, disturbances in such
mechanisms can produce contractile changes,
which may be relevant for arterial blood
pressure homeostasis. Indeed, the conse-
quence of the inhibition of the sarcolemmal
Na+ pump is an enhanced responsiveness of
vascular smooth muscle to constrictor agents
(2).
It is now known that all three isoforms of
the Na+,K+-ATPase a subunit have distinct
sensitivities for cardiac glycosides and all
are expressed in rat tail arteries and aorta (6).
The presence of high-affinity isoforms in the
vasculature raises the possibility that, even
at low levels, endogenous ouabain may act
as a modulator increasing tone or pressor
responses to endogenous vasoactive agents
(5). This possibility is reinforced by the de-
scription of ouabain as an endogenous com-
pound existing in human plasma (7) and in
several other animal species (8,9).
The purpose of the present study was to
determine whether ouabain at concentrations
similar to the endogenous ones can increase
vascular tone and enhance phenylephrine-
induced vasoconstriction in vivo and in vitro
in normotensive control, uninephrectomized,
hypertensive one kidney, one clip (1K1C)
rats and in deoxycorticosterone acetate
(DOCA)-salt rats.
Material and Methods
Experimental animals
Studies were performed on 129 male
Wistar rats weighing 200 to 380 g, divided
into five main groups: 22 control rats (nor-
motensive rats), 58 uninephrectomized rats,
21 DOCA-salt-treated rats, and 28 1K1C
rats. The care and use of the laboratory ani-
mals were in accordance with NIH guide-
lines. All rats had free access to water and rat
chow ad libitum.
Hypertension models
Renovascular hypertension. With rats
under ether anesthesia, renovascular hyper-
tension (Goldblatt 1K1C model) was pro-
duced by application of a silver clip (0.2-mm
internal diameter) to the left renal artery,
combined with nephrectomy of the right kid-
ney through an abdominal incision. Weight-
matched control rats were uninephrectomized
and submitted to right-side nephrectomy
without the clip application. After these pro-
cedures, muscle layers were reconnected,
and the skin incision was closed. Rats were
placed in plastic cages with supplies of water
and chow for 30 days.
DOCA-salt hypertension. Male 45-day-
old rats were uninephrectomized under
ether anesthesia. Four days later the ani-
mals were treated with either DOCA (8
mg/kg twice a week) or vehicle (soybean
oil, 0.25 ml/animal). This treatment was
repeated twice a week for 30 days. The
vehicle-treated uninephrectomized rats
drank water and the DOCA-salt rats drank
saline solution (0.9% NaCl) during the
treatment.
The day before the experiments the sys-
tolic blood pressure of all rats was measured
using a tail-cuff method (IITC Model 29
Pulse Amplifier, IITC Inc., Santa Barbara,
CA, USA). Animals which did not develop
hypertension were excluded.
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Anesthetized animals
At the end of the treatments, rats were
anesthetized with urethane (1.8 g/kg, ip),
supplemented when necessary. The jugular
vein and the carotid artery were dissected
and cannulated with a polyethylene catheter
(PE-50 with heparinized saline) for drug
infusion and arterial blood pressure meas-
urements, respectively. Arterial blood pres-
sure was measured with a pressure trans-
ducer (Gold P23XL) connected to an MP
100 amplifier (FUNBEC, Sªo Paulo, SP,
Brazil) and recorded on a polygraphic re-
corder (RG 300, FUNBEC). ECG was also
measured using standard procedures.
The following protocol was used for all
groups. Pressor reactivity was investigated by
measuring arterial blood pressure and by in-
jecting (iv) increasing doses of phenylephrine
(0.1, 0.25 and 0.5 µg) administered in small
volumes (5 µl or less) before and 1 h after
ouabain treatment. All groups of rats were
divided into three subgroups and each sub-
group was treated with either 0.18 µg/kg, 18
µg/kg or 1.8 mg/kg ouabain. Ouabain treat-
ments were employed based on the human
loading doses, but taking into consideration
that the rat is more resistant to ouabain. In
humans, acute digitalization with ouabain is
obtained with 4 to 5 µg/kg. We then adminis-
tered ouabain covering the range of toxic (1.8
mg/kg) and non-toxic doses (18 µg/kg), in-
cluding a very small dose (0.18 µg/kg) which
is expected to produce plasma concentrations
at the nanomolar level. Systolic and diastolic
blood pressure and the ECG were monitored
continuously for heart rate evaluation.
Isolated rat tail vascular bed prepara-
tion. Isolated rat tail vascular beds were
used in this study as previously reported
(10). Briefly, the rats were anesthetized with
sodium pentobarbital (65 mg/kg, ip) and
heparin (500 IU, ip) was administered after
loss of the righting reflex. Ten minutes after
the administration of heparin, 1 cm of the
tail artery was dissected free and cannulated
with an intracath (Gelco 24) near the base of
the tail. The vascular bed was flushed with
Krebs-Henseleit buffer (KHB) (120 mM
NaCl, 5.4 mM KCl, 1.2 mM MgCl2, 1.25 mM
CaCl2, 2.0 mM NaH2PO4, 27 mM NaHCO3,
11 mM glucose, and 0.03 mM EDTA) bubbled
with 5% CO2-95% O2 at 36 – 0.5oC. The tail
was then severed from the body and placed in
a tissue bath and perfused with KHB at a
constant flow of 2.5 ml/min with a peristaltic
pump (Milan, Colombo, PR, Brazil). After a
30- to 45-min equilibration period, the exper-
imental protocol was initiated. Mean perfu-
sion pressure was measured with a pressure
transducer (TP-200T, Nihon-Kohden con-
nected to an MP-100 pressure amplifier,
FUNBEC) and the data were recorded using an
interface and software for computer data ac-
quisition, BIOPAC MP100A (Biopac System,
Inc., Santa Barbara, CA, USA) with a sample
rate of 500 Hz per channel. Because a constant
flow was maintained, changes in the perfusion
pressure represented changes in vascular resis-
tance. The following protocol was used.
After 30 min stabilization bolus injec-
tions of increasing doses of phenylephrine
(0.5, 1, 2, 5 and 10 µg, in 100 µl) were
administered in the absence or in the pres-
ence of 10 nM ouabain. The second dose-
response curve was constructed 1 h after
continuous infusion of KHB containing 10
nM ouabain. At the end of the experiment,
preparations were contracted by continuous
infusion of phenylephrine (100 nM) and en-
dothelial integrity was tested using bolus in-
jection of acetylcholine (5 µg in 100 µl).
Endothelial integrity of the preparations was
considered adequate when relaxation in re-
sponse to acetylcholine attained 50% or more.
This protocol was performed in preparations
from normotensive (control, N = 6, and uni-
nephrectomized, N = 8) and hypertensive
(1K1C, N = 7, and DOCA-salt, N = 7) rats.
Statistical analysis
Results are reported as means – SEM.
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Results regarding perfusion pressure meas-
urements are presented as changes in the
mean perfusion pressure calculated by sub-
tracting peak pressure from baseline pres-
sure. Data were analyzed by the Student t-
test and ANOVA. When the ANOVA showed
a significant treatment effect, the Tukey post
hoc test was used to compare the different
treatment groups. The level of significance
was set at P<0.05.
Drugs and reagents used
Deoxycorticosterone acetate, urethane,
L-phenylephrine hydrochloride, acetylcho-
line chloride, and ouabain octahydrate were
purchased from Sigma Chemical Co. (St.
Louis, MO, USA). Heparin was purchased
from Roche (Sªo Paulo, SP, Brazil) and
pentobarbital sodium was purchased from
Fontoverter (Itapira, SP, Brazil).
Results
On the day before the experiments the
systolic blood pressure was measured in
awake unrestrained animals and the DOCA-
salt and 1K1C hypertension was confirmed
(Table 1). The systolic blood pressure meas-
ured after 30 days was higher in 1K1C than
in DOCA-salt rats.
Anesthetized animals
After urethane anesthesia, systolic and
diastolic blood pressure were reduced in all
models and this reduction was significantly
larger in the 1K1C and DOCA-salt groups
(Table 1).
Figure 1 shows the time-course changes
of systolic blood pressure for 1 h after 18 µg/
kg ouabain administration (iv) in all groups.
Between 1 to 3 min after injection, systolic
blood pressure increased and then decreased
back to control values (approximately 15 to
20 min) after which it increased slowly again.
It is interesting to note that this systolic
blood pressure increment became signifi-
cant only after 40 min. Heart rate did not
change after ouabain treatment and the
changes produced by phenylephrine injec-
tions were similar both before and after oua-
bain (data not shown).
The administration of 18 µg/kg ouabain
caused a similar increase in systolic blood
pressure after 1 h in all groups studied (Fig-
ure 2). Diastolic blood pressure did not
change significantly after this dose of oua-
bain in control rats but increased in the other
groups, including uninephrectomized rats
(Figure 3). Analysis of the changes in dia-
stolic pressure before and 1 h after 18 µg/kg
ouabain showed that hypertensive rats had a
significant enhancement of diastolic pres-
Table 1. Systolic (SBP) and diastolic (DBP) blood pressure in normotensive (control, CT;
uninephrectomized, UNR) and hypertensive (1K1C and DOCA-salt) awake and anes-
thetized rats.
Awake rats Anesthetized rats
SBP (mmHg) SBP (mmHg) DBP (mmHg)
CT 127 ± 3.5 101 ± 1.8 74 ± 2.6
UNR 126 ± 2.3 98 ± 1.8 72 ± 1.9
1K1C 184 ± 6.7+# 104 ± 3.5#* 76 ± 3.6#
DOCA-salt 141 ± 6.5+ 94 ± 2.3+* 60 ± 2.3+
+P<0.01, comparison between hypertensive and normotensive rats;
#P<0.01, comparison between 1K1C and DOCA-salt rats;
*P<0.05, comparison between hypertensive anesthetized and awake rats (t-test).
Figure 1. Time course of sys-
tolic blood pressure (SBP)
changes during 1-h treatment
with 18 µg/kg ouabain in normo-
tensive (control, CT; uninephrec-
tomized, UNR) and hypertensive
(1K1C and DOCA-salt) rats after
anesthesia. Points represent the
means ± SEM. *P<0.05 com-
pared to before ouabain treat-
ment (time zero) for all groups
(ANOVA).
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Figure 2. Changes in systolic blood pressure (SBP) in
response to increasing doses of phenylephrine (PHE) in
normotensive (control, CT; uninephrectomized, UNR)
and hypertensive (1K1C and DOCA-salt) rats before
(open symbols) and after (closed symbols) treatment
with 18 µg/kg ouabain. Points represent the means ±
SEM. *P<0.05 compared to before ouabain treatment
(ANOVA).
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Figure 3. Changes in diastolic blood pressure (DBP) in
response to increasing doses of phenylephrine (PHE) in
normotensive (control, CT; uninephrectomized, UNR)
and hypertensive (1K1C and DOCA-salt) rats before
(open symbols) and after (closed symbols) treatment
with 18 µg/kg ouabain. Points represent the means ±
SEM. *P<0.05 compared to before ouabain treatment
(ANOVA).
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sure compared to the normotensive controls
(normotensive - control: 8.50 – 2.62 mmHg;
uninephrectomized: 16.41 – 3.47 mmHg,
P>0.05 vs control, t-test, and hypertensive -
1K1C: 20.10 – 3.13 mmHg, P<0.02 vs con-
trol, t-test; DOCA-salt: 21.71 – 4.20, P<0.03
vs control, t-test). When pressor reactivity
was tested (Figures 2 and 3), it could be seen
that dose-dependent phenylephrine-evoked
systolic and diastolic blood pressure re-
sponses were shifted upwards. However,
ouabain did not change the gain of this re-
sponse.
Treatment with 0.18 µg/kg ouabain pro-
duced a smaller but significant increment in
systolic blood pressure and had no signifi-
cant effect on diastolic blood pressure in the
control rats (Figures 4 and 5). This dose is
expected to produce nanomolar levels of
circulating ouabain if we assume that the
drug is being diluted in 40 ml of extracellular
fluid per each 100 g of rat. In normotensive
rats, phenylephrine-evoked pressor effects
were similar before and after ouabain treat-
ment. However, this very low dose of oua-
bain increased both systolic and diastolic
blood pressure in the hypertensive groups
(1K1C and DOCA-salt), and in the uni-
nephrectomized rats (Figures 4 and 5). When
pressor reactivity was tested (Figures 4 and
5) it could be seen that dose-dependent phen-
ylephrine-evoked systolic and diastolic blood
pressure responses were shifted upwards.
Moreover, analysis of the magnitude of sys-
tolic and diastolic pressure increment before
and 1 h after 0.18 µg/kg ouabain showed that
DOCA-salt rats were more responsive to the
effects of ouabain than normotensive and
1K1C hypertensive rats (Table 2).
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Figure 4. Changes in systolic blood pressure (SBP) in response to increasing doses of
phenylephrine (PHE) in normotensive (control, CT; uninephrectomized, UNR) and hyperten-
sive (1K1C and DOCA-salt) rats before (open symbols) and after (closed symbols) treatment
with 0.18 µg/kg ouabain. Points represent the means ± SEM. *P<0.05 compared to before
ouabain treatment (ANOVA).
Figure 5. Changes in diastolic blood pressure (DBP) in
response to increasing doses of phenylephrine (PHE) in
normotensive (control, CT; uninephrectomized, UNR)
and hypertensive (1K1C and DOCA-salt) rats before
(open symbols) and after (closed symbols) treatment
with 0.18 µg/kg ouabain. Points represent the means ±
SEM. *P<0.05 compared to before ouabain treatment
(ANOVA).
*
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Another dose of ouabain was used. Since
we knew from previous experiments that
SHR are more resistant to toxic doses of
ouabain, another protocol was performed
using 1.8 mg/kg ouabain to test this behavior
in another hypertensive group. 1K1C rats
and their uninephrectomized controls were
investigated and both behaved like SHR,
with an increase in systolic and diastolic
blood pressure after ouabain treatment (Table
3).
Isolated rat tail vascular bed preparation
Phenylephrine produced a dose-de-
pendent increase in mean perfusion pres-
sure in the rat tail vascular bed from all
animals (Figure 6). This increment did not
differ between normotensive and 1K1C
hypertensive rats but was smaller in
DOCA-salt rats compared to the other
groups (Figure 6).
After treatment with 10 nM ouabain for
60 min, the baseline perfusion pressure was
reduced in all animals (normotensive: con-
trol, from 74 – 3.24 to 66 – 1.60 mmHg, and
uninephrectomized, from 79 – 4.88 to 64 –
3.13 mmHg; hypertensive: 1K1C, from 82 –
6.85 to 67 – 2.12 mmHg, and DOCA-salt,
from 77 – 6.13 to 61 – 4.93 mmHg; P<0.05
for all groups, paired t-test). Perfusion with
ouabain-free Krebs solution for 1 h also
reduced the baseline perfusion pressure but
did not enhance the pressor response to phen-
ylephrine (data not shown). After ouabain
treatment the pressor response to phenyl-
ephrine was significantly enhanced only at
the 5- and 10-µg doses in normotensive and
1K1C hypertensive rats (Figure 6). How-
ever, in DOCA-salt hypertensive rats the
increment of the pressor response obtained
after ouabain treatment became significant
at a lower dose of phenylephrine, i.e., 1 µg
(Figure 6).
Table 3. Changes in systolic (SBP) and diastolic (DBP) arterial blood pressure (in mmHg) in response to the vasopressor effects of increasing doses
of phenylephrine (PHE) before and after 1.8 mg/kg ouabain treatment in normotensive (control, CT; uninephrectomized, UNR) and hypertensive
(1K1C) rats.
PHE (0) PHE (0.1 µg) PHE (0.25 µg) PHE (0.5 µg)
SBP DBP SBP DBP SBP DBP SBP DBP
CT Before 109 ± 9.4 79 ± 10.6 120 ± 9.4 90 ± 10.4 120 ± 6.9 93 ± 8.1 124 ± 6.7 98 ± 7.9
After 88 ± 4.4* 78 ± 6.1 98 ± 7.7* 85 ± 5.9 102 ± 10.5* 87 ± 7.2 100 ± 10.2* 90 ± 7.6
UNR Before 99 ± 4.9 72 ± 5.3 104 ± 4.5 78 ± 4.6 107 ± 3.9 81 ± 4.6 110 ± 3.7 85 ± 4.6
After 114 ± 5.3* 93 ± 5.3* 119 ± 5.2* 97 ± 5.1* 120 ± 4.7* 97 ± 5.2* 123 ± 5.1* 102 ± 5.2*
1K1C Before 112 ± 6.1 81 ± 5.9 121 ± 6.4 92 ± 6.5 123 ± 6.5 94 ± 6.3 127 ± 6.5 98 ± 6.3
After 141 ± 7.7* 116 ± 7.8* 145 ± 7.6* 118 ± 7.6* 147 ± 7.8* 120 ± 7.8* 150 ± 8.0* 123 ± 8.0*
*P<0.05 compared to before ouabain treatment (ANOVA).
Table 2. Changes in systolic (SBP) and diastolic
(DBP) blood pressure before and after 0.18 µg/kg
ouabain in normotensive (control, CT; uninephrec-
tomized, UNR) and hypertensive (1K1C and
DOCA-salt) rats.
DSBP (mmHg) DDBP (mmHg)
CT 7.6 ± 3.6 3.7 ± 3.6
UNR 9.3 ± 2.7 9.2 ± 3.1
1K1C 12.7 ± 4.2 10.7 ± 3.8
DOCA-salt 24.3 ± 2.6*+ 27.2 ± 3.5*+
*P<0.001, comparison between hypertensive and
normotensive rats;
+P<0.001, comparison between DOCA-salt and
1K1C rats (t-test).
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Discussion
The present results suggest that DOCA-
salt rats were more sensitive to pressor ef-
fects after treatment with small doses of
ouabain (0.18 µg/kg) than normotensive and
1K1C rats in vivo. When using higher doses
of ouabain (18 µg/kg) the hypertensive 1K1C
and DOCA-salt rats showed similar behav-
ior regarding the pressor effects induced by
this digitalis compound. Although ouabain
did not increase sensitivity to phenylephrine
in vivo, this effect was observed in vitro in
isolated vessels obtained from DOCA-salt
rats. These findings suggest that the increase
of arterial pressure caused by small doses of
ouabain in DOCA-salt rats seems to be the
result of an increased sensitization of vascu-
lar smooth muscle to pressor a-agonist
agents. Our results also suggest that the pres-
sor response to ouabain depends on the dose
and on the hypertensive animal model used.
Ouabain inhibits Na+,K+-ATPase by bind-
ing to the a subunits of the enzyme in several
tissues like the heart, vessels, kidneys and
the nervous system (3,6,11). The cell mem-
brane enzyme Na+,K+-ATPase is the bio-
chemical expression of the electrogenic Na+
pump and exchanges 3 Na+ for 2 K+, main-
taining the resting potential of excitable cells
(3). A reduction in Na+ pump activity leads
to Na+ accumulation in the myoplasm (4).
Inhibition of the pump also affects the Na+/
Ca2+ exchange mechanism and, conse-
quently, the amount of activator Ca2+ neces-
sary for contraction in several tissues such as
vascular smooth muscle (4). By inhibiting
the Na+ pump, ouabain may have effects on
the homeostatic mechanisms affecting the
regulatory control of blood pressure, there-
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fore playing a central role in the develop-
ment and maintenance of hypertension (4).
Indeed, many reports have suggested such a
role since ouabain can produce hypertension
during long-term administration in rats
(9,12,13).
Recently, ouabain has been reported to
be an adrenocortical hormone present in
plasma at nanomolar or subnanomolar con-
centrations (4,8,9). There are results indicat-
ing that a circulating ouabain-like substance
is increased in DOCA-salt rats and in low-
renin rat models such as 1K1C (14,15). A
recent study using anesthetized normoten-
sive and SHR rats has reported that the pres-
sor effects induced by ouabain were opera-
tive in vivo (1). In SHR, sensitization was
present at doses of ouabain reaching the
nanomolar level. This effect was observed
when vascular smooth muscle was challenged
by phenylephrine stimulation after ouabain
treatment. Therefore, the possibility of sen-
sitization by ouabain may manifest in vivo
since vascular smooth muscle is continu-
ously stimulated by the sympathetic drive or
by the presence of endogenous vasopressor
substances. The present study was designed
to investigate the vascular reactivity of anes-
thetized 1K1C and DOCA-salt rats after sev-
eral ouabain treatments.
As seen in Table 3, a toxic dose of oua-
bain (1.8 mg/kg) produced a hypotensive
effect in normotensive rats but not in the
other groups. It has been reported that nor-
motensive rats show a reduction of systolic
blood pressure after this ouabain treatment
while SHR show an increase in systolic blood
pressure (1). Diastolic blood pressure did
not change significantly after 1.8 mg/kg oua-
bain treatment in normotensive rats but in-
creased in the others. Also, confirming pre-
vious findings (1), this large dose of ouabain
frequently produced arrhythmias in normo-
tensive rats, characterizing a toxic effect.
The hypotension was probably caused by a
reduction in cardiac output produced by the
presence of arrhythmias in the normotensive
group or by a putative calcium overload
causing diastolic dysfunction. This suggests
that hypertensive and uninephrectomized rats
are more resistant to the toxic effects of
ouabain than normotensive rats.
The arrhythmogenic effect of ouabain is
also related to the inhibition of Na+,K+-
ATPase. This inhibition increases intracel-
lular sodium concentration and depolarizes
the cell. The Na+/Ca2+ exchange activity is
also reduced and Ca2+ accumulates inside
the cell. Once intracellular Ca2+ increases,
the Na+/Ca2+ exchanger is stimulated and,
since this is an electrogenic exchange, depo-
larizing currents are generated causing ar-
rhythmias (16). The resistance to the toxic
effects of ouabain in the hypertensive group
has been explained by the fact that Na+,K+-
ATPase activity is reduced in hypertrophic
hearts from hypertensive animals (17,18).
Moreover, some of these reports show that
the a2 isoform of Na+,K+-ATPase is reduced
(18) while the a3 isoform increases (19).
Since the a3 isoform is less sensitive to
intracellular Na+ (19), this could explain the
increased resistance of the hypertrophied
myocardium to the effects of this digitalis
compound.
The intermediate dose of ouabain (18 µg/
kg) increased arterial systolic blood pressure
after 1 h. It is interesting to note that ouabain,
even at the largest dose, never increased
significantly the diastolic blood pressure of
normotensive rats, which reflects the lack of
effects on systemic peripheral resistance.
However, a significant diastolic blood pres-
sure increment was observed after all oua-
bain treatments in other groups. It should be
emphasized that, although we did not ob-
serve differences among groups, when the
changes in systolic pressure were evaluated
after 18 µg/kg ouabain, this dose was able to
increase diastolic pressure in hypertensive
animals when compared to normotensive
animals. This result was similar to what was
reported before for SHR (1), indicating that
the effect of ouabain on arterial blood pres-
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sure is larger in these animals. Ouabain treat-
ment with the smaller dose of 0.18 µg/kg
was able to increase arterial pressure. How-
ever, in contrast to what occurred when 18
µg/kg ouabain was used, this pressure incre-
ment was larger in DOCA-salt rats than in
normotensive and 1K1C rats. These data
show that not all hypertension models have
the same sensitivity to ouabain at very small
doses. Treatment with ouabain increased ar-
terial pressure and shifted upwards the vaso-
pressor responses to phenylephrine in all
models at all doses studied. However, no
changes in the gain of phenylephrine pressor
responses were observed. An interesting re-
sult was obtained with the uninephrectomized
rats whose response to ouabain reached an
intermediate level between hypertensive and
normotensive control rats. This was not the
only difference they showed compared to
normal rats, since a reduction of cardiac
contractility was also reported following uni-
nephrectomy (20). These findings led us to
conclude that uninephrectomized animals
cannot be considered as a normal control.
Our results, however, cannot discriminate
the underlying mechanisms responsible for
this sensitization effect but suggest that a)
ouabain increases blood pressure and main-
tains phenylephrine-evoked pressor re-
sponses in all groups studied when acute
digitalization doses are used, b) these effects
are still present even when smaller doses of
ouabain are used in all groups of rats except
the normotensive ones, c) the increment in
systolic and diastolic blood pressure is more
efficient in DOCA-salt hypertensive rats,
and d) hypertensive and uninephrectomized
rats are less sensitive to toxic doses of oua-
bain.
One possible mechanism that explains
the changes in pressor responses caused by
ouabain in these models of hypertension is a
vascular mechanism. Previous reports have
demonstrated that higher doses of ouabain
sensitize the contractile response to a-adre-
nergic agonists and to KCl in 1K1C rats
(21,22). The same occurs with DOCA-salt
rats in which ouabain treatment increased
even more the pressor responses (23). This
would help to explain why 18 µg/kg ouabain
was capable to produce a significant increase
of diastolic pressure in hypertensive, but not
normotensive rats. However, these results
were obtained with higher doses of ouabain
and this may mask a different effect obtained
with lower doses of ouabain. Indeed, the
effect obtained in DOCA-salt rats after 0.18
µg/kg ouabain could be explained by such
enhanced sensitization of the vascular bed.
It has been reported that low plasma con-
centrations of ouabain may modulate vascu-
lar reactivity without directly affecting vas-
cular smooth muscle tone (2,24,25). For ex-
ample, low ouabain concentrations (10 nM)
increase caffeine-evoked contractions in rat
aortic rings (26). Using a perfused rat tail
vascular bed preparation we showed (2,24)
that 10 nM ouabain did not alter baseline
perfusion pressure but increased the sensi-
tivity to phenylephrine-evoked pressor re-
sponses both in normotensive rats and SHR.
The same was observed in our normotensive
control rats. Ouabain was able to sensitize
the pressor response to phenylephrine in the
tail vascular bed from all models studied,
without causing changes in baseline perfu-
sion pressure.
Recently, it has been shown that small
increments of myoplasmic Ca2+ may increase
vascular reactivity because of the amplifier
action of the sarcoplasmic reticulum (4,5).
Thus, low concentrations of ouabain can
augment Ca2+ transients in vascular smooth
muscle without increasing cytosolic sodium
(25). This mechanism explains why low con-
centrations of ouabain increase the contrac-
tile response to phenylephrine without caus-
ing contraction by a direct action on vascular
smooth muscle. However, by comparing the
sensitization of the phenylephrine pressor
response among the studied models it was
possible to see that in vitro treatment with 10
nM ouabain is more effective in DOCA-salt
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rats when compared with normotensive and
hypertensive 1K1C rats. This result also ex-
plains why low doses of ouabain caused a
larger pressor response in DOCA-salt rats
compared to 1K1C. Possible mechanisms
that could be modified in these models of
hypertension and could explain the results
described here are changes in the expression
and activity of the Na+ pump.
The expression and activity of Na+,K+-
ATPase and its a isoform are regulated by
multiple factors such as developmental stage
(27), hormones (28), endothelial factors (29)
and the occurrence of hypertension (30,31).
Furthermore, it has been shown that a sub-
units of Na+,K+-ATPase consist of different
a1, a2 and a3 subunits with different affini-
ties for digitalis (11). Since the Na+,K+-
ATPase isoforms may change under several
situations the maintenance of the sensitizing
mechanism could be of clinical relevance.
Recently, Blaustein et al. (5) suggested that a
special distribution of the a2 and a3 isoforms
of Na+,K+-ATPase exists in the sarcolemma
that binds ouabain preferentially and they
are located near the vesicles of the sarcoplas-
mic reticulum. This special localization en-
ables the increment of cytosolic calcium near
the reuptake sites, facilitating the operation
of the proposed mechanism. Then, when
vascular smooth muscle is stimulated the
final result is an amplification of the cal-
cium released and an increase in the re-
sponse of the vasculature to agents that pro-
duce constriction (1,2,24,26). This is an
amplification mechanism that operates even
at low ouabain concentrations.
These results lead us to speculate that
there might be differences in Na+,K+-ATPase
isoforms in these normotensive and hyper-
tensive rats. One possible explanation for
this difference would be the up-regulation in
hypertensive groups. Recently, Liu et al.
(31) reported up-regulation of both a1 and a2
isoforms after a 2- or 4-day stretch in cul-
tured vascular smooth muscle cells. Similar
results have been obtained in several models
of cardiac hypertrophy (18,19,32). Increase
of Na+ pump activity and up-regulation of
the expression of a1 mRNA in the heart,
together with a down-regulation of the a2
mRNA as a result of DOCA-salt hyperten-
sion, has been reported (6,30). However,
increased a1 isoform activity would result in
low levels of inhibition by ouabain sufficient
to make 1K1C and uninephrectomized rats
more resistant to the toxic effects of the drug.
In the aorta, it has been reported that cortico-
steroids regulate Na+,K+-ATPase isoform ex-
pression and activity in vascular tissue, sug-
gesting a mineralocorticoid-dependent modu-
lation of the a2 isoform (28). Also, up-regu-
lation of the a2 isoform in DOCA-salt hyper-
tensive rats may facilitate ouabain binding,
further increasing its sensitizing effects.
The ability of ouabain to elevate arterial
pressure in anesthetized rats might be the
result of a peripheral and central pathway.
Ouabain is reported to activate the sympa-
thetic autonomic nervous system and to re-
duce the efficiency of the baroreflex, which
in turn, contributes to an increase in arterial
pressure (33). In addition, hypertension has
been reported to occur with enhanced sym-
pathetic activity and a blunted baroreflex in
1K1C and DOCA-salt rats (34,35). Thus, a
putative effect of ouabain potentiating this
mechanism cannot be ruled out. Another
important finding supported by our results is
the fact that ouabain directly enhances the
release of norepinephrine from nerve termi-
nals (36). Moreover, greater vascular reac-
tivity to vasopressor agents, increased endo-
thelin levels and an increased activity of the
renin-angiotensin system have been reported
to occur in both 1K1C and DOCA-salt rats
(37,38). Thus, sensitization of the vascular
smooth muscle by ouabain, associated with
the greater release of norepinephrine by nerve
terminals, might explain the increase of dia-
stolic pressure produced by ouabain. Al-
though ouabain sensitizes the vessels to the
pressor effect of phenylephrine in vitro, this
action did not occur in vivo. In vivo, the
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pressor effects of phenylephrine were dis-
placed upwards but no sensitization was ob-
served. Part of this response can be explained
by the action of ouabain or by the arterial
pressure elevation stimulating the barore-
flex. Also, there are reports showing that
ouabain, instead of blunting the baroreflex,
can enhance it in normotensive animals, an
effect that is amplified in SHR (39). On this
basis, we may suppose that a putative in vivo
sensitization might be masked by this effect.
Another interesting aspect is related to
the fact that the in vitro pressor responses to
phenylephrine are reduced in DOCA-salt
rats compared to the other models studied.
Previous reports have shown that in DOCA-
salt rats the chronic increment of sympa-
thetic tone in vascular beds with more sym-
pathetic innervation, like the mesenteric ar-
teries, might reduce the response of these
arteries to norepinephrine. Prolonged expo-
sure to high levels of norepinephrine may
reduce the action of a-adrenergic agonists
via stimulation of the vascular endothelium,
leading to an increased production of va-
sodilator factors like nitric oxide (40). This
mechanism should explain the reduction of
the pressor response to phenylephrine of the
tail vascular bed from DOCA-salt rats since
the tail artery is highly innervated. In addi-
tion, previous results from our laboratory
have suggested that endothelial modulation
of the pressor response to phenylephrine is
enhanced in DOCA-salt rats.
In conclusion, these results suggest that
ouabain treatment increases blood pressure
and that this increment is more marked in
hypertensive rats. The pressor effects after
the administration of low ouabain concen-
trations were more pronounced in hyperten-
sive DOCA-salt rats in vivo and in vitro.
These increments still occurred with very
low doses of ouabain in hypertensive rats,
suggesting an enhanced pressor reactivity
which may contribute to the genesis and
maintenance of hypertension.
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